Objective This study presents estimates of the impact of changes in California tobacco control funding on healthcare expenditures for 2012e2016 under four funding scenarios. Methods Smoking prevalence is projected using a cointegrated time series regression model. Smokingattributable healthcare expenditures are estimated with econometric models that use a prevalence-based annual cost approach and an excess cost methodology.
INTRODUCTION
California has one of the longest running comprehensive tobacco control programs in the world. The California Tobacco Control Program (CTCP) was established in 1989, with a cigarette tax increase of 25 cents per pack and 5 cents per pack earmarked for tobacco control activities. The CTCP uses a comprehensive multipronged approach for preventing and reducing tobacco use with a strategy of promoting social norms that tobacco use and exposure to second-hand smoke (SHS) are not acceptable. 1 CTCP activities include a statewide anti-tobacco media campaign, school-based prevention and cessation programs, communitybased interventions, a competitive grants program, healthcare provider education, restrictions on advertising and promotion and clean indoor air laws. 2 Since the program was implemented, the state has benefitted from substantial reductions in adult smoking prevalence, 3 heavy smoking prevalence, 4 adolescent smoking initiation 5 and per capita cigarette consumption, 6 7 as well as reduced lung cancer rates, 8 9 reduced heart disease mortality 6 and a reduction in healthcare expenditures due to reduced smoking-related diseases. 10 Other states' tobacco control programs have also been associated with positive outcomes, including reduced per capita cigarette consumption and healthcare expenditures in Arizona, 11 reduced teen smoking prevalence in Florida 12 and reduced adult cigarette consumption and smoking prevalence in Massachusetts. 13 While strong tobacco control programs have been shown to reduce smoking and related health and expenditure impacts, there are also troubling indications that these impacts diminish over time. 13 Once considered a national leader in tobacco control programs, California has fallen behind in its funding of tobacco control programs. CTCP funding level has not increased since the program was implemented, and the real value of this funding has eroded over time due to inflation. The US Centers for Disease Control and Prevention (CDC) produces guidelines for the minimum tobacco control funding levels and programmatic recommendations for each state. 14 These are determined through an expert panel review of estimates of effectiveness of the components of large state tobacco control programs, particularly California and Massachusetts. In the 2007 guidelines, the CDC recommended that California spend $441.9 million, or $12.12 per capita a year, 14 but California spent only $75.0 million in fiscal year 2011 on tobacco control programs. This ranks California 23rd in funding levels among all states. 15 The purpose of the present study was to estimate the impact of changes in California tobacco control funding on smoking prevalence and healthcare expenditures under four funding scenarios.
METHODS
We evaluate changes in smoking prevalence and smoking-attributable healthcare expenditures for 2012e2016 resulting from funding changes that would begin in 2012. The four funding scenarios are as follows: < Scenario 1: base case. Tobacco control funding will continue at the current level of 5 cents per pack, and cigarette taxes remain unchanged. This is comparable to $1.50e$2.00 per capita, depending on future population growth. < Scenario 2: funding cut in half. Current funding is assumed to be cut in half to 2.5 cents per pack holding cigarette taxes unchanged. This would amount to $.75e$1.00 per capita. 
Data sources
Several data sets were used for projecting smoking behaviour under alternative scenarios, estimating the national healthcare cost of smoking models and applying the models to California.
Behavioural Risk Factor Surveillance System
The 
Types of healthcare expenditures
Expenditures were estimated for hospitalisations, ambulatory care, prescription drugs and home healthcare. Expenditures include all direct payments for healthcare services: out-of-pocket payments and payments by private insurance, Medicaid, Medicare and other sources. 16 Healthcare expenditures were converted to constant 2009 dollars, using the medical care component of the Consumer Price Index. 17 Projected smoking prevalence for each year and scenario
The overall current smoking prevalence and the proportions of California current smokers who were light, moderate and heavy smokers from two data sourcesdthe 1984e2000 BRFSS and the TUS-CPS (available years 1992e2007)dwere the four dependent variables. Next, median regression was used to estimate a cointegrated time series regression model 18 19 that regressed each dependent variable on the following explanatory variables: average current smoking prevalence for a group of control states (see online appendix 1 for the details of control state selection), difference in cumulative real per capita tobacco control funding between California and the control states, difference in real per capita income between California and the control states and a dummy variable indicating the data source (BRFSS vs TUS-CPS). The control states were used to model unobservable national trends that may affect smoking prevalence apart from California tobacco control expenditures, such as national trends in attitudes towards cigarette smoking, per capita income and cigarette price. 20 The coefficients of the cointegrating regression were estimated using the irrelevant instrumental variables estimator. 21 Irrelevant instrumental variables are artificially generated instruments designed to be correlated with the explanatory variables using properties of non-stationary time series and by construction, they are not correlated with regression errors. 21 Based on these estimated coefficients, we forecast the long-run total current smoking prevalence and proportions of current smokers by intensity for 2007e2016 under each of the four scenarios. These forecasts were based on the predicted values of the explanatory variables produced with a reduced form vector autoregression specification. Finally, the predicted prevalence of light, moderate and heavy smoking for 2007e2016 was calculated by multiplying the predicted proportions of current smokers by intensity by the predicted total current smoking prevalence. Further details of the prevalence estimation and projections are provided in online appendix 1.
We adjusted the prevalence projections so that the predicted 2007 smoking prevalence rates are set to equal the actual prevalence rates estimated from the 2007 CHIS data because the smoking-attributable health expenditure estimates are based on a model that uses that data (see the Smoking-attributable healthcare expenditures analysis section). We determined the projected former and never smoking rates for 2008e2016 by allocating the change in current smoking rates between 2007 and the projection year equally to former-and never-smokers. We also examined the sensitivity of our results to two alternative assumptions regarding changes in current smoking prevalence: < Former smoking rates remain unchanged, and all the differences are allocated to never-smokers. < Never smoking rates remain unchanged, and all the differences are allocated to former smokers.
Smoking-attributable healthcare expenditures analysis
Smoking-attributable healthcare expenditures for adults aged 18 years and older were estimated with the econometric models that Max and colleagues have developed and refined over the past 2 decades. 22 23 The models use a prevalence-based annual cost approach and an excess cost methodology. After estimating the annual healthcare expenditures as a function of smoking status and covariates, the estimated coefficients were used to generate two sets of predicted healthcare expenditures for each smoker (ie, current light, current moderate, current heavy or former smoker): one for a factual case and one for a counterfactual casedthat is, for someone who has all the same characteristics as the smoker except that they are assumed to be a never-smoker. The difference between the factual and the counterfactual predictions among all smokers is the excess cost of smoking. This excess cost divided by total predicted healthcare expenditures among all individuals (including smokers and neversmokers) is the smoking-attributable fraction (SAF). The ratio of mean predicted expenditures between smokers and neversmokers is the relative risk (RR) of healthcare expenditures.
National models of smoking-attributable healthcare expenditures were estimated first (see online appendix 2) because data on both smoking and healthcare expenditures are not available in any one data set for California. The estimated coefficients from the national models were then applied to the 2007 CHIS data to obtain California RRs and SAFs, which were forecast to 2012. These SAFs were then applied to projected state health expenditures by type of healthcare services for each year to obtain smoking-attributable healthcare expenditures. A detailed description of the model estimation and healthcare expenditure projection is included in online appendix 3.
RESULTS

Smoking prevalence
Current, former and never smoking prevalence under the four scenarios for 2010e2011 (baseline) and 2012e2016 (forecast) is shown in table 1. Current smoking prevalence rises under both the base case scenario and the funding cut scenario, rising more rapidly under the latter. Under the tax scenario, current smoking prevalence would drop dramatically during the first year and then continue to drop more gradually to 10.4% in 2016. If funding is increased to the CDC recommended level, current smoking prevalence would fall more gradually over time to 10.6% in 2016.
Looking at the impact of funding changes on total current smoking prevalence does not tell the whole story, as illustrated in figure 1 , which shows the impact of funding changes on light, moderate and heavy smoking. The base case scenario results in light smoking prevalence remaining flat, while both moderate and heavy smoking prevalence increases slightly. The effect is more pronounced under the funding cut scenario, where light smoking prevalence falls slightly and the increases in moderate and heavy smoking prevalence are greater. If the tobacco tax is increased, there is an initially large reduction in the prevalence of all intensities of smoking in the first year, followed by a slight increase in light smoking prevalence and a continual decrease in moderate and especially heavy smoking prevalence. Under the CDC funding scenario, although total current smoking prevalence would fall steadily over time, the separate impacts on light, moderate and heavy smoking show mixed patterns: light smoking prevalence increases, moderate smoking prevalence drops substantially and there is a dramatic 10-fold drop in heavy smoking prevalence. This suggests that a considerable proportion of heavy and moderate smokers would reduce their cigarette consumption instead of quitting smoking. We tested for statistically significant differences in smoking prevalence by intensity (light, moderate and heavy) between the base case and the other three scenarios by year for 2012e2016 and found that the time trends of expected differences between base case and other scenarios in prevalence of light, moderate and heavy smoking were statistically significantly different at the 5% level.
Smoking-attributable healthcare expenditures
Smoking-attributable healthcare expenditures under the four scenarios are shown in table 2, along with the annual and cumulative savings compared to the base case scenario.
Under the base case scenario, smoking-attributable expenditures for current smokers would increase from $3.5 billion in 2011 to $4.3 billion in 2016, while expenditures for former smokers would increase from $2.8 billion to $3.2 billion over the same time period, for a total of $7.5 billion in healthcare expenditures attributable to ever-smokers in 2016.
If funding for tobacco control programs is cut in half to 2.5 cents a pack, there would be a slight worsening of the situation compared to the base case scenario. Smoking-attributable healthcare expenditures for ever-smokers would increase from $6.4 billion in 2011 to $7.6 billion in 2016. This represents an increase in smoking-attributable healthcare expenditures of $307 million over the 5 years from 2012 to 2016 compared to the base case scenario. The tax increase scenario would lead to a substantial reduction in healthcare expenditures during the first year, followed by an increasing trend during 2012e2016. Compared to the base case scenario, savings per year would increase from $434 million in 2012 to $917 million in 2016, for a total savings of $3.3 billion over the 5-year period.
If funding for tobacco control programs is increased to $12.12 per capita as recommended by the CDC, there would also be a drop in healthcare expenditures in the first year, though less than under the tax increase scenario, followed by continued reduction during 2012e2016. Savings per year compared to the base case would be $310 million in 2012 and continue to increase to $1.6 billion in 2016, for a total savings of $4.7 billion during 2012e2016. Compared to the tax scenario, healthcare savings are larger, even though total smoking prevalence will fall by less because the CDC funding scenario would result in a much larger reduction in heavy smoking prevalence, and the RRs of healthcare expenditures for heavy smokers are larger than the RRs for light smokers according to our estimated models.
Sensitivity analysis
We conducted a sensitivity analysis to see how our estimates of smoking-attributable healthcare expenditures under the four funding scenarios would vary with the assumption about the allocation of changes in current smoking rates to former-and never-smokers. We varied the proportion of change attributed to former smoking from 0 to 50 to 100%. Compared to the 50% case, savings estimates varied by À17% to +15%, indicating that the results are relatively insensitive to this assumption.
DISCUSSION
Our findings indicate that the CTCP has a large impact on healthcare expenditures in the state, consistent with other studies for California 10 and Arizona. 11 We find that increasing funding for the program could result in 5-year savings of as much as $4.7 billion if the CDC recommended funding level is achieved.
Lightwood et al 10 found that the CTCP saved $86 billion (2004 dollars) over the 16 years from 1989 to 2004, a much larger estimate than ours. There are several explanations for this difference. First, their model was based on a comparison of California with a group of 38 control states that did not have tobacco control programs, comparing the impact of the California's comprehensive tobacco control program with the complete lack of a program, whereas we compared changes in funding levels. Second, their model is based on a macroeconomic time series model that predicts aggregated California healthcare expenditures using state-level measures, while our model is based on microeconomic individual-level survey data analysis and includes individual socioeconomic characteristics. Third, their model included the impact of both active smoking and SHS exposure on healthcare expenditures and included all types of healthcare services used by adults and children in the state. We limited our analysis to healthcare expenditures attributable to active smoking for adults only, though children, adolescents and even unborn infants exposed in utero also incur excess healthcare costs as a result of smoking. Our estimates of healthcare costs included ambulatory care, prescription medications, inpatient hospitalisations and home healthcare. These categories accounted for almost 90% of healthcare costs. Including other types of costs resulting from smoking, such as nursing home care and dental care, would increase our estimates.
Our approach uses a long-run equilibrium model. The forecasts should be interpreted as indicating expected trends over 5 years, and the forecasts of year to year changes should not be overinterpreted. The short-run adjustment process may spread the change over more than one calendar year. It must be noted that the absolute levels of the forecasts are influenced by assumptions about the evolution of price, prevalence and per capita income in the control states. Thus, the forecasts are best used to compare the relative trends across scenarios for California.
Our results show an initially large reduction in smoking prevalence and smoking-attributable healthcare expenditures under the tax increase scenario. This is due to the two-prong impact of a $1.00 per pack tax increase and 20 cents per pack funding increase. The tax increase has an immediate price effect on reducing demand for cigarettes. The increased program funding would also immediately reduce smoking. However, in the longer term, it is difficult to tease out the separate effects of the tax-induced price increases and the program funding increases because they are closely interrelated. As the price increases reduce demand for cigarettes, tax revenues fall and program funding would fall. This would lead to a further change in demand, which in turn would change tax revenues and then program funding. This feedback loop makes it difficult to calculate simple measures of how much of the impact is from the tax-induced price increases and how much from the increase in program funding. Estimating the separate effect of taxes and program funding is a topic for further research.
Some limitations of our analysis should be acknowledged. First, in addition to the exclusion of the impact of SHS exposure, some age groups and some types of healthcare expenditures, we did not estimate the value of time lost from work and other productive activities due to illness or disability attributable to smoking. Second, our model is based on the well-established excess cost approach in which expenditures are compared for smokers and a hypothetical group of 'non-smoking smokers' who are the same as smokers in every way except for their smoking behaviour. 24 This approach was developed to take account of the fact that smokers and never-smokers are known to differ in ways other than smoking status. Thus, it is not appropriate to compare smokers and never-smokers by attributing all the difference in their healthcare costs to smoking only. However, there is evidence that when smokers quit, they behave differently than they did as smokers and become more similar to never-smokers, 25 for example, spending money previously used to purchase cigarettes for health improving goods and services and adopting other healthy behaviours. Assuming that smoking behaviour change will not lead to changes in an individual's other behaviours likely produces conservative estimates of the cost of smoking. The causal role of smoking in the development of 'non-smoking smoker's' other health risk behaviours is not understood well enough for a more precise analysis at this time. All these limitations suggest that we may be underestimating the impact of tobacco control funding on healthcare expenditures. Our model estimates the impact of changes on tobacco control funding in the relatively short-term. It is possible that a successful tobacco control program will result in greater longevity among quitters and smokers who smoke fewer cigarettes. This could potentially have a different impact on healthcare expenditures in the long run, as might any intervention that leads to longer life. 26 Finally, our estimates are point estimates and do not account for the sampling variability in the estimation and projection of smoking prevalence or healthcare expenditures.
CONCLUSIONS
California has one of the most successful tobacco control programs in the world. However, even if the nominal funding provided by the program is not changed, the program is in jeopardy because inflation is eroding the purchasing power of the 5 cents per pack currently allocated to tobacco control activities. Maintaining funding at the current level will lead to a gradual increase in smoking prevalence and healthcare expenditures over the next 5 years. Cutting the funding would only exacerbate the situation. If tobacco control funding is increased, smoking prevalence would decrease, especially among heavy and moderate smokers. This would lead to savings in healthcare expenditures as early as 2012. The magnitude of the changes and the timing of the changes in prevalence and healthcare expenditures depend on the amount by which tobacco control funding is changed.
Investing in tobacco control yields substantial returns. Increasing funding per capita to the CDC recommended level in California would cost approximately $403 million per year but would reduce healthcare expenditures by $4.7 billion over the first 5 years. It is not enough to implement a strong tobacco control program. Funding levels must keep pace with inflation and be increased in order to sustain effective tobacco control programs and to continue to reduce tobacco-related illness and save healthcare dollars into the future.
What this paper adds < Tobacco control programs implemented in many states in the USA and worldwide have successfully reduced smoking prevalence, disease rates and mortality from smoking-related diseases and healthcare expenditures. However, there has also been evidence suggesting that these programs become less effective over time. < This study analyses the relationship between tobacco control funding and smoking prevalence and healthcare expenditures in California. < By comparing the impact of four different funding scenarios, we found that maintaining funding at the current level will lead to an increase in smoking prevalence and healthcare expenditures due to the erosion of funding in real terms over time. < It is necessary that funding keeps pace with inflation and that funding levels are increased in order to maintain effectiveness at reducing smoking prevalence and saving healthcare costs.
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